Answers are grounded in this paper and cite their sources.
Real-world study shows Foslevodopa/Foscarbidopa infusion improves nocturia in advanced Parkinson's disease, indicating enhanced quality of life.
Background Nocturia is considered as one of the commonest nonmotor symptoms in people with Parkinson's disease ( PD ), highly impacting on quality‐of‐life and health‐related costs. Objectives Aim of our real‐world study was to evaluate the impact of Foslevodopa/Foscarbidopa ( LDp / CDp ) subcutaneous infusion ( CSCI ) on nocturia in a group of advanced PD patients. Methods Seventy‐eight patients were enrolled in seven Movement Disorders outpatient clinics. International Prostatic Symptoms Scale ( IPSS ) and Nocturia Quality of Life ( NQoL ) questionnaire were administrated before starting LDp / CDp CSCI and after three months of infusion. Results In this cohort, LDp / CDp CSCI significantly improved urinary disturbances, nocturia and quality of life. Age and baseline MDS ‐ UPDRS score negatively influenced urinary disturbances and quality of life changes during the treatment, while post‐pre changes of IPSS and LEED showed a negative correlation. Conclusions This study supports the utility of the overnight dopaminergic stimulation with LDp / CDp CSCI in controlling overactive bladder.
No takes yet. Share an insight, caveat, or question.
Brusa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: